Guardant Health, Inc.GH
Guardant Health, Inc. Financial Overview 2021–2025
Updated Aug 15, 2026Fueled by the commercial launch of its Shield blood test, Guardant Health saw its early screening revenue explode by 633% in Q1 2026, validating the company's costly push into primary cancer detection. The core investment thesis is clear: Guardant is a high-growth, high-burn clinical powerhouse capturing massive market share in precision oncology, even as its profitability remains deeply constrained by commercialization costs.
The company has demonstrated relentless top-line execution, with total revenue scaling rapidly from $373.7 million in FY2021 to $982.0 million in FY2025. This expansion is underpinned by soaring clinical test volumes and improving reimbursement rates, though it continues to demand heavy capital outlays. In FY2025, Guardant Health posted a $416.3 million net loss, driven heavily by a 36% year-over-year spike in sales and marketing expenses to $494.7 million. Despite these persistent deficits, the balance sheet remains fortified, closing FY2025 with $1.3 billion in cash and marketable debt securities to fund ongoing operations and commercial rollouts.
Investors have largely rewarded this growth-at-all-costs trajectory, pricing the diagnostics leader based on its expanding clinical footprint rather than near-term earnings. At the close of FY2025, the market valued the company at a $13.3 billion market cap. Shares traded at $102.14 alongside a negative -$3.32 earnings per share, reflecting a premium valuation tied directly to the anticipated long-term adoption of its early-detection portfolio.
Recent Developments (Q1 and Q2 2026)
Guardant Health generated $335.0 million in revenue during Q2 2026, marking a 44% year-over-year increase. This top-line growth was driven by a 257% jump in Shield test volumes and FDA approval for the Guardant360 Liquid CDx test. Sales and marketing expenses rose 59% during the quarter, contributing to a $120.1 million net loss. The company experienced leadership turnover following the resignation of its Chief Medical Officer in May 2026.
Bulls focus on expanding clinical volume supported by a $1.2 billion cash balance. Bears highlight ongoing net losses and a $0 to $250 million contingent liability tied to a TwinStrand patent infringement verdict. The stock trades at a -44.6x P/E ratio alongside a $19.3 billion market cap as of the July 30, 2026 report.
What to watch: TwinStrand patent lawsuit appeal developments; successor appointment for the Chief Medical Officer role.
Rev
$982.0M
FY2025
NI
$-416.3M
FY2025
EPS
$-3.32
FY2025
OCF
$-184.8M
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
All GH Financial Metrics(59)
Income Statement
Balance Sheet
- Cash & ST Investments
- Total Assets
- Current Assets
- Cash
- Short-Term Investments
- Receivables
- Inventory
- Prepaid & Other
- PP&E
- Goodwill
- Intangibles
- Other Non-current
- Total Liabilities
- Current Liabilities
- Accounts Payable
- Accrued Liabilities
- Deferred Revenue
- Long-Term Debt
- Other Non-current Liab.
- Equity
- Retained Earnings
- Accumulated OCI
- APIC
- Treasury Stock
- Total L&E
- Shares Outstanding
Cash Flow
Recent SEC Filings
Guardant Health, Inc. 8-K Report, Financial Results (Jul 30, 2026)
Guardant Health, Inc. (GH) has filed an 8-K report on July 30, 2026, to announce its financial results for the fiscal quarter ended June 30, 2026. The primary purpose of this filing is to furnish the accompanying press release, which contains the detailed financial and operational performance for the period. Investors should refer to Exhibit 99.1, the press release itself, for the specific figures and management commentary regarding revenue, profitability, and key performance indicators. While the 8-K itself provides a formal notification of the release, the substantive information is contained within the press release. Investors are advised to carefully review this press release for insights into the company's top-line growth, cost management, and any forward-looking guidance provided by Guardant Health. This information is crucial for assessing the company's current financial health and future prospects within the competitive landscape of precision oncology.
Guardant Health, Inc. 8-K Report, Shareholder Vote Results (Jun 18, 2026)
Guardant Health, Inc. (GH) held its Annual Meeting of Stockholders on June 17, 2026, with the results detailed in this 8-K filing. Key outcomes include the election of all director nominees and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The company also sought advisory votes on executive compensation and the frequency of future advisory votes on executive compensation. While director elections and auditor ratification were strongly supported by shareholders, the advisory vote on executive compensation ("Say-on-Pay") did not receive majority approval. This indicates a potential disconnect between management's compensation practices and shareholder sentiment. Furthermore, shareholders voted overwhelmingly in favor of an annual advisory vote on executive compensation, suggesting a desire for more frequent engagement on this matter.
Guardant Health, Inc. 8-K Report, Financial Results (May 7, 2026)
Guardant Health, Inc. (GH) filed an 8-K on May 7, 2026, to report its financial results for the fiscal quarter ended March 31, 2026. The press release, furnished as Exhibit 99.1, provides the key financial and operational data investors need to assess the company's performance. Investors should review this press release for details on revenue, profitability, cash flow, and any forward-looking guidance. While specific financial figures are not detailed within the 8-K itself, the filing serves as the official channel for disseminating this crucial information. The incorporation by reference of the press release means that all information contained within it is considered part of the company's public disclosures. Investors are advised to access Exhibit 99.1 directly for a comprehensive understanding of Guardant Health's first-quarter 2026 performance and its implications for future growth and market position.
Guardant Health, Inc. 8-K Report, Executive Changes (Apr 27, 2026)
Guardant Health, Inc. (GH) announced a significant change in its executive leadership with the resignation of its Chief Medical Officer, Craig Eagle, M.D., effective May 8, 2026. This departure marks the end of Dr. Eagle's tenure in a critical role overseeing the company's medical strategy and clinical development, particularly relevant given Guardant Health's focus on cancer diagnostics and precision medicine. Investors will be keen to understand the implications of this change on the company's ongoing research, clinical trial progress, and its overall medical vision moving forward. The company has not yet announced a successor for Dr. Eagle. The absence of immediate plans for a replacement could suggest a period of transition or a strategic review of the CMO role. Investors should closely monitor future filings and communications from Guardant Health for updates on leadership appointments and any potential shifts in the company's medical and scientific direction.
Guardant Health, Inc. 8-K Report, Financial Results (Feb 19, 2026)
Guardant Health, Inc. (GH) has filed an 8-K on February 19, 2026, to announce its financial results for the fiscal quarter and year ended December 31, 2025. The key details of these results are contained within a press release furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for specific performance metrics, revenue figures, profitability, and any forward-looking guidance provided by the company. While the 8-K itself is a procedural filing, the accompanying press release is the critical document for understanding Guardant Health's recent financial performance and its outlook. Investors will be looking for information regarding the growth in their diagnostic testing volume, reimbursement trends, and progress in commercializing their liquid biopsy solutions for cancer detection and monitoring. Any updates on clinical trial progress or regulatory approvals for their products would also be highly relevant.
View all 8-K filings →